董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Casey Tansey | 男 | Director | 68 | 未披露 | 379.35 | 2026-05-07 |
| Cynthia Lucchese | 女 | Director | 65 | 13.83万美元 | 4.88 | 2026-05-07 |
| Maxwell Bikoff | 男 | Director | 40 | 未披露 | 未持股 | 2026-05-07 |
| William Harrington | 男 | Director | 66 | 未披露 | 287.76 | 2026-05-07 |
| Richard Foust | 男 | President, Chief Executive Officer and Director | 52 | 190.63万美元 | 70.42 | 2026-05-07 |
| Edward Hanlon | 男 | Director | 30 | 未披露 | 未持股 | 2026-05-07 |
| Dana G. Mead, Jr. | 男 | Chair of the Board | 67 | 13.83万美元 | 6.61 | 2026-05-07 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Chase Leavitt | 男 | General Counsel and Corporate Secretary | 44 | 未披露 | 未持股 | 2026-05-07 |
| Douglas Ellison | 男 | Chief Commercial Officer | 63 | 134.48万美元 | 18.82 | 2026-05-07 |
| Nelson Bunker Curnes | 男 | Chief Financial Officer | 43 | 未披露 | 142.70 | 2026-05-07 |
| Richard Foust | 男 | President, Chief Executive Officer and Director | 52 | 190.63万美元 | 70.42 | 2026-05-07 |
| Prashant Rawat | 男 | Chief Operating Officer | 52 | 96.15万美元 | 23.97 | 2026-05-07 |
董事简历
中英对照 | 中文 | 英文- Casey Tansey
-
Casey Tansey自2008年1月以来一直担任我们的董事会成员。Tansey先生自2014年8月起担任风险投资公司U.S.Venture Partners“；USVP”；的管理合伙人，并于2005年4月至2014年7月担任USVP的管理成员。Tansey先生曾于2006年至2017年担任IntersectEnt，Inc.董事会成员，并于2008年10月至2017年10月担任ReShape Medical，Inc.董事会成员。Tansey先生拥有圣母学院（College of Notre Dame）的学士学位和工商管理硕士学位。
Casey Tansey,has served on Shoulder Innovations board of directors since October 2020. Since 2014, Mr. Tansey has served as the Managing Partner of USVP Management Company. Mr. Tansey has been a member of the board of directors of Inspire Medical Systems, Inc.(NYSE: INSP) since 2007 and of UCSF MTVP Investment Advisory since 2017. He has also served on the boards of several other medical technology and healthcare-related companies, including Cagent Vascular, HeartFlow, Inc., Highlife Medical, Inc., Luminopia, Inc., MicroTransponder, Inc., Neuros Medical, NeoChord, Inc., and ShiraTronics. He received a B.S. in Business and a M.B.A. in Business from the College of Notre Dame. - Casey Tansey自2008年1月以来一直担任我们的董事会成员。Tansey先生自2014年8月起担任风险投资公司U.S.Venture Partners“；USVP”；的管理合伙人，并于2005年4月至2014年7月担任USVP的管理成员。Tansey先生曾于2006年至2017年担任IntersectEnt，Inc.董事会成员，并于2008年10月至2017年10月担任ReShape Medical，Inc.董事会成员。Tansey先生拥有圣母学院（College of Notre Dame）的学士学位和工商管理硕士学位。
- Casey Tansey,has served on Shoulder Innovations board of directors since October 2020. Since 2014, Mr. Tansey has served as the Managing Partner of USVP Management Company. Mr. Tansey has been a member of the board of directors of Inspire Medical Systems, Inc.(NYSE: INSP) since 2007 and of UCSF MTVP Investment Advisory since 2017. He has also served on the boards of several other medical technology and healthcare-related companies, including Cagent Vascular, HeartFlow, Inc., Highlife Medical, Inc., Luminopia, Inc., MicroTransponder, Inc., Neuros Medical, NeoChord, Inc., and ShiraTronics. He received a B.S. in Business and a M.B.A. in Business from the College of Notre Dame.
- Cynthia Lucchese
-
Cynthia Lucchese自2019年11月以来一直担任我们的董事会成员。自2015年11月起，Lucchese女士一直担任Hulman&Company（一家赛车比赛和娱乐公司）的首席行政官兼首席财务官。在此之前，她曾于2008年1月至2014年3月担任Hillenbrand，Inc.的高级副总裁兼首席财务官，该公司是一家上市公司，拥有多个品牌，服务于全球多个行业。Lucchese女士拥有医疗设备和生命科学公司的经验，包括Guidant，Thoratec和Eli Lilly。Lucchese女士目前在两家上市公司的董事会任职。自2014年7月以来，她一直担任IntersectEnt，Inc.（一家公开上市的医疗器械公司）的董事会成员、审计委员会主席以及提名和公司治理委员会成员。此外，自2015年5月起，Lucchese女士一直担任Hanger，Inc.的董事会成员，该公司是一家提供矫形和修复产品以及患者护理的上市公司。Lucchese女士于2017年11月成为Hanger&8217；的审计委员会成员，此前曾担任薪酬委员会成员。Lucchese女士也是BVI International，Inc.（一家私人拥有的全球眼科设备公司）的董事会成员和审计委员会主席。Lucchese女士拥有印第安纳大学凯利商学院（Indiana University，Kelley School of Business）会计学士学位和工商管理硕士学位。
Cynthia Lucchese has served as a member of board of directors since November 2019. Since November 2015 Ms. Lucchese has been the Chief Administrative Officer and Chief Financial Officer of Hulman & Company, a motorsports competition and entertainment company. Prior to this she was the Senior Vice President and Chief Financial Officer of Hillenbrand, Inc., a public company with multiple brands that serve a range of industries across the globe, from January 2008 until March 2014. Ms. Lucchese has experience with medical device and life sciences companies, including Guidant, Thoratec and Eli Lilly. Ms. Lucchese currently serves on the board of two public companies. Since July 2014 she has been a board member and serves as Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee of Intersect ENT, Inc., a publicly traded medical device company. Additionally, Ms. Lucchese has been a board member of Hanger, Inc., a public company that delivers orthotic and prosthetic products and patient care, since May 2015. Ms. Lucchese became a member of Hanger's Audit Committee in November 2017 and previously was a member of the Compensation Committee. Ms. Lucchese is also a board member and Audit Committee Chair for BVI International, Inc., a privately owned global ophthalmic device company. Ms. Lucchese has a B.S. in accounting and an M.B.A. from Indiana University, Kelley School of Business. - Cynthia Lucchese自2019年11月以来一直担任我们的董事会成员。自2015年11月起，Lucchese女士一直担任Hulman&Company（一家赛车比赛和娱乐公司）的首席行政官兼首席财务官。在此之前，她曾于2008年1月至2014年3月担任Hillenbrand，Inc.的高级副总裁兼首席财务官，该公司是一家上市公司，拥有多个品牌，服务于全球多个行业。Lucchese女士拥有医疗设备和生命科学公司的经验，包括Guidant，Thoratec和Eli Lilly。Lucchese女士目前在两家上市公司的董事会任职。自2014年7月以来，她一直担任IntersectEnt，Inc.（一家公开上市的医疗器械公司）的董事会成员、审计委员会主席以及提名和公司治理委员会成员。此外，自2015年5月起，Lucchese女士一直担任Hanger，Inc.的董事会成员，该公司是一家提供矫形和修复产品以及患者护理的上市公司。Lucchese女士于2017年11月成为Hanger&8217；的审计委员会成员，此前曾担任薪酬委员会成员。Lucchese女士也是BVI International，Inc.（一家私人拥有的全球眼科设备公司）的董事会成员和审计委员会主席。Lucchese女士拥有印第安纳大学凯利商学院（Indiana University，Kelley School of Business）会计学士学位和工商管理硕士学位。
- Cynthia Lucchese has served as a member of board of directors since November 2019. Since November 2015 Ms. Lucchese has been the Chief Administrative Officer and Chief Financial Officer of Hulman & Company, a motorsports competition and entertainment company. Prior to this she was the Senior Vice President and Chief Financial Officer of Hillenbrand, Inc., a public company with multiple brands that serve a range of industries across the globe, from January 2008 until March 2014. Ms. Lucchese has experience with medical device and life sciences companies, including Guidant, Thoratec and Eli Lilly. Ms. Lucchese currently serves on the board of two public companies. Since July 2014 she has been a board member and serves as Chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee of Intersect ENT, Inc., a publicly traded medical device company. Additionally, Ms. Lucchese has been a board member of Hanger, Inc., a public company that delivers orthotic and prosthetic products and patient care, since May 2015. Ms. Lucchese became a member of Hanger's Audit Committee in November 2017 and previously was a member of the Compensation Committee. Ms. Lucchese is also a board member and Audit Committee Chair for BVI International, Inc., a privately owned global ophthalmic device company. Ms. Lucchese has a B.S. in accounting and an M.B.A. from Indiana University, Kelley School of Business.
- Maxwell Bikoff
-
Maxwell Bikoff是子公司Kestra Medical Technologies，Inc.的董事会成员，自2024年以来一直担任这一职务。Bikoff先生自2025年以来一直担任董事会成员。Bikoff先生是Longitude Capital的董事总经理，他于2016年加入该公司。Bikoff先生目前担任Polares Medical的董事会成员，并且是Bolt Medical和FIRE1的董事会观察员。Bikoff先生此前曾在Amphora（已被收购）、Ceribell（纳斯达克：CBLL）、Eargo（纳斯达克：EAR）、Endogenex、LimFlow（已被收购）、Nalu Medical和RxSight（纳斯达克：RXST）担任董事会观察员，还积极参与了Longitude Capital对Axonics Modulation Technologies（纳斯达克：AXNX）和PROCEPT BioRoboticsTERM10（纳斯达克：PRCT）的投资。Bikoff先生于2010年至2016年在卡地纳健康担任一系列战略、财务和运营职务，包括2014年至2016年心血管设备投资组合的北美市场营销总监。Bikoff先生的职业生涯始于德勤咨询公司的生命科学战略实践，并拥有杜克大学生物医学工程BSE。
Maxwell Bikoff,is a member of the Board of Directors of subsidiary, Kestra Medical Technologies, Inc., and has served in such role since 2024. Mr. Bikoff has been a member of Board of Directors since 2025. Mr. Bikoff is a managing director at Longitude Capital, which he joined in 2016. Mr. Bikoff currently serves on the board of Polares Medical and is a board observer at Bolt Medical and FIRE1. Mr. Bikoff previously served as a board observer at Amphora (which has since been acquired), Ceribell (Nasdaq: CBLL), Eargo (Nasdaq: EAR), Endogenex, LimFlow (which has since been acquired), Nalu Medical, and RxSight (Nasdaq: RXST), and was also actively involved in Longitude Capital's investments in Axonics Modulation Technologies (Nasdaq: AXNX) and PROCEPT BioRobotics (Nasdaq: PRCT). Mr. Bikoff held a series of strategy, finance, and operating roles at Cardinal Health from 2010 to 2016, including director of Marketing, North America for a portfolio of cardiovascular devices from 2014 to 2016. Mr. Bikoff began his career in Deloitte Consulting's Life Sciences Strategy practice and holds a BSE in Biomedical Engineering from Duke University. - Maxwell Bikoff是子公司Kestra Medical Technologies，Inc.的董事会成员，自2024年以来一直担任这一职务。Bikoff先生自2025年以来一直担任董事会成员。Bikoff先生是Longitude Capital的董事总经理，他于2016年加入该公司。Bikoff先生目前担任Polares Medical的董事会成员，并且是Bolt Medical和FIRE1的董事会观察员。Bikoff先生此前曾在Amphora（已被收购）、Ceribell（纳斯达克：CBLL）、Eargo（纳斯达克：EAR）、Endogenex、LimFlow（已被收购）、Nalu Medical和RxSight（纳斯达克：RXST）担任董事会观察员，还积极参与了Longitude Capital对Axonics Modulation Technologies（纳斯达克：AXNX）和PROCEPT BioRoboticsTERM10（纳斯达克：PRCT）的投资。Bikoff先生于2010年至2016年在卡地纳健康担任一系列战略、财务和运营职务，包括2014年至2016年心血管设备投资组合的北美市场营销总监。Bikoff先生的职业生涯始于德勤咨询公司的生命科学战略实践，并拥有杜克大学生物医学工程BSE。
- Maxwell Bikoff,is a member of the Board of Directors of subsidiary, Kestra Medical Technologies, Inc., and has served in such role since 2024. Mr. Bikoff has been a member of Board of Directors since 2025. Mr. Bikoff is a managing director at Longitude Capital, which he joined in 2016. Mr. Bikoff currently serves on the board of Polares Medical and is a board observer at Bolt Medical and FIRE1. Mr. Bikoff previously served as a board observer at Amphora (which has since been acquired), Ceribell (Nasdaq: CBLL), Eargo (Nasdaq: EAR), Endogenex, LimFlow (which has since been acquired), Nalu Medical, and RxSight (Nasdaq: RXST), and was also actively involved in Longitude Capital's investments in Axonics Modulation Technologies (Nasdaq: AXNX) and PROCEPT BioRobotics (Nasdaq: PRCT). Mr. Bikoff held a series of strategy, finance, and operating roles at Cardinal Health from 2010 to 2016, including director of Marketing, North America for a portfolio of cardiovascular devices from 2014 to 2016. Mr. Bikoff began his career in Deloitte Consulting's Life Sciences Strategy practice and holds a BSE in Biomedical Engineering from Duke University.
- William Harrington
-
William Harrington自2022年6月起担任Mobia Medical，Inc.董事会成员。自2012年以来，Harrington博士还担任Osage University Partners的管理合伙人，负责监督生物技术和医疗设备行业的投资活动。他目前在Neuros Medical，Inc.、Hyalex Orthopedics，Inc.、Transposon Therapeutics，Inc.和MediSix Therapeutics Pte. Ltd.的董事会任职。此前，他曾在医疗器械公司Nevro Corp.的董事会任职。哈林顿博士获得了塔夫茨大学的学士学位、哈佛医学院的医学博士学位，以及加州大学伯克利分校哈斯商学院的工商管理硕士学位。
William Harrington has served as a member of Mobia Medical, Inc.'s board of directors since June 2022. Dr. Harrington has also served as a Managing Partner at Osage University Partners since 2012, where he oversees investing activities across biotechnology and medical device industries. He currently serves on the boards of directors of Neuros Medical, Inc., Hyalex Orthopedics, Inc., Transposon Therapeutics, Inc. and MediSix Therapeutics Pte. Ltd. Previously, he served on the board of directors of Nevro Corp., a medical device company. Dr. Harrington received a B.S. from Tufts University, an M.D. from Harvard Medical School, and an M.B.A. from the Haas School of Business at University of California, Berkeley. - William Harrington自2022年6月起担任Mobia Medical，Inc.董事会成员。自2012年以来，Harrington博士还担任Osage University Partners的管理合伙人，负责监督生物技术和医疗设备行业的投资活动。他目前在Neuros Medical，Inc.、Hyalex Orthopedics，Inc.、Transposon Therapeutics，Inc.和MediSix Therapeutics Pte. Ltd.的董事会任职。此前，他曾在医疗器械公司Nevro Corp.的董事会任职。哈林顿博士获得了塔夫茨大学的学士学位、哈佛医学院的医学博士学位，以及加州大学伯克利分校哈斯商学院的工商管理硕士学位。
- William Harrington has served as a member of Mobia Medical, Inc.'s board of directors since June 2022. Dr. Harrington has also served as a Managing Partner at Osage University Partners since 2012, where he oversees investing activities across biotechnology and medical device industries. He currently serves on the boards of directors of Neuros Medical, Inc., Hyalex Orthopedics, Inc., Transposon Therapeutics, Inc. and MediSix Therapeutics Pte. Ltd. Previously, he served on the board of directors of Nevro Corp., a medical device company. Dr. Harrington received a B.S. from Tufts University, an M.D. from Harvard Medical School, and an M.B.A. from the Haas School of Business at University of California, Berkeley.
- Richard Foust
-
Richard Foust自2022年1月起担任Mobia Medical，Inc.董事会成员和Mobia Medical，Inc.首席执行官，并自2025年10月起担任Mobia Medical，Inc.总裁兼首席执行官。Mr. Foust co创立了3D Strategy Consulting，LLC，这是一家医疗保健咨询服务公司，自2015年2月起担任其首席执行官。Foust先生此前曾于2018年11月至2020年11月担任医疗设备公司Velano Vascular，Inc.的首席商务官，并于2015年5月至2018年2月担任数字健康公司Analyte Health，Inc.的首席商务官。Foust先生还在Abbott Vascular，Inc.担任过不断升级的职务，包括West Area Vascular销售高级总监和Vascular Global Marketing & BioResorbable Vascular Scaffold高级总监。Foust先生在埃默里大学获得应用物理学学士学位，在乔治亚理工学院获得生物工程专业的机械工程硕士学位。
Richard Foust has served as a member of Mobia Medical, Inc.'s board of directors and as Mobia Medical, Inc.'s Chief Executive Officer since January 2022 and has served as Mobia Medical, Inc.'s President and Chief Executive Officer since October 2025. Mr. Foust co founded 3D Strategy Consulting, LLC, a healthcare consulting services company, and has served as its Chief Executive Officer since February 2015. Mr. Foust previously served as the Chief Commercial Officer at Velano Vascular, Inc., a medical device company, from November 2018 to November 2020, and as the Chief Business Officer at Analyte Health, Inc., a digital health company, from May 2015 to February 2018. Mr. Foust also had escalating roles at Abbott Vascular, Inc., including Senior Director, West Area Endovascular Sales and Senior Director, Endovascular Global Marketing & Bioresorbable Vascular Scaffold. Mr. Foust received a B.S. in Applied Physics from Emory University and an M.S. in Mechanical Engineering with a major in Bioengineering from Georgia Institute of Technology. - Richard Foust自2022年1月起担任Mobia Medical，Inc.董事会成员和Mobia Medical，Inc.首席执行官，并自2025年10月起担任Mobia Medical，Inc.总裁兼首席执行官。Mr. Foust co创立了3D Strategy Consulting，LLC，这是一家医疗保健咨询服务公司，自2015年2月起担任其首席执行官。Foust先生此前曾于2018年11月至2020年11月担任医疗设备公司Velano Vascular，Inc.的首席商务官，并于2015年5月至2018年2月担任数字健康公司Analyte Health，Inc.的首席商务官。Foust先生还在Abbott Vascular，Inc.担任过不断升级的职务，包括West Area Vascular销售高级总监和Vascular Global Marketing & BioResorbable Vascular Scaffold高级总监。Foust先生在埃默里大学获得应用物理学学士学位，在乔治亚理工学院获得生物工程专业的机械工程硕士学位。
- Richard Foust has served as a member of Mobia Medical, Inc.'s board of directors and as Mobia Medical, Inc.'s Chief Executive Officer since January 2022 and has served as Mobia Medical, Inc.'s President and Chief Executive Officer since October 2025. Mr. Foust co founded 3D Strategy Consulting, LLC, a healthcare consulting services company, and has served as its Chief Executive Officer since February 2015. Mr. Foust previously served as the Chief Commercial Officer at Velano Vascular, Inc., a medical device company, from November 2018 to November 2020, and as the Chief Business Officer at Analyte Health, Inc., a digital health company, from May 2015 to February 2018. Mr. Foust also had escalating roles at Abbott Vascular, Inc., including Senior Director, West Area Endovascular Sales and Senior Director, Endovascular Global Marketing & Bioresorbable Vascular Scaffold. Mr. Foust received a B.S. in Applied Physics from Emory University and an M.S. in Mechanical Engineering with a major in Bioengineering from Georgia Institute of Technology.
- Edward Hanlon
-
Edward Hanlon自2025年3月起担任Mobia Medical，Inc.董事会成员。Hanlon先生是Gilde Healthcare的投资总监，他于2020年2月加入该公司，负责监督医疗器械行业临床阶段和成长期公司的投资活动。此前，Hanlon先生曾于2017年9月至2020年2月担任Health Advances的高级分析师。Hanlon先生自2025年2月起担任医疗器械公司VS3 Medical，Inc.的董事会成员，此前曾于2023年2月至2025年7月担任Shoulder Innovations（NYSE：SI）的董事会观察员。Hanlon先生获得了杜克大学的生物学学士学位。
Edward Hanlon has served as a member of Mobia Medical, Inc.'s board of directors since March 2025. Mr. Hanlon is an investment director at Gilde Healthcare which he joined in February 2020, overseeing investing activities across clinical stage and growth stage companies in the medical device industry. Previously, Mr. Hanlon was a senior analyst at Health Advances from September 2017 to February 2020. Mr. Hanlon has served as a member of the board of directors of VS3 Medical, Inc., a medical device company, since February 2025 and previously served as a board observer at Shoulder Innovations (NYSE: SI) from February 2023 to July 2025. Mr. Hanlon received a B.S. in Biology from Duke University. - Edward Hanlon自2025年3月起担任Mobia Medical，Inc.董事会成员。Hanlon先生是Gilde Healthcare的投资总监，他于2020年2月加入该公司，负责监督医疗器械行业临床阶段和成长期公司的投资活动。此前，Hanlon先生曾于2017年9月至2020年2月担任Health Advances的高级分析师。Hanlon先生自2025年2月起担任医疗器械公司VS3 Medical，Inc.的董事会成员，此前曾于2023年2月至2025年7月担任Shoulder Innovations（NYSE：SI）的董事会观察员。Hanlon先生获得了杜克大学的生物学学士学位。
- Edward Hanlon has served as a member of Mobia Medical, Inc.'s board of directors since March 2025. Mr. Hanlon is an investment director at Gilde Healthcare which he joined in February 2020, overseeing investing activities across clinical stage and growth stage companies in the medical device industry. Previously, Mr. Hanlon was a senior analyst at Health Advances from September 2017 to February 2020. Mr. Hanlon has served as a member of the board of directors of VS3 Medical, Inc., a medical device company, since February 2025 and previously served as a board observer at Shoulder Innovations (NYSE: SI) from February 2023 to July 2025. Mr. Hanlon received a B.S. in Biology from Duke University.
- Dana G. Mead, Jr.
-
Dana G. Mead, Jr.，自2008年7月起担任董事会成员。Mead先生于2019年5月至2021年2月担任HeartFlow，Inc.的首席执行官兼总裁，HeartFlow，Inc.是一家改变心脏病诊断和治疗方式的数字健康公司。2016年至2019年5月，Mead先生担任Beaver-Visitec International，Inc.的首席执行官兼总裁，Beaver-Visitec International，Inc.是一家外科手术设备开发商和制造商。从2005年到2016年，Mead先生在风险投资公司Kleiner Perkins Caufield & Byers担任合伙人。除了在董事会任职外，Mead先生自2015年6月起担任医疗技术公司Intersect ENT，Inc.的董事会成员，自2008年起担任Pulmonx Corporation的董事会成员。2011年5月至2016年12月，Mead先生在远程健康公司Teladoc, Inc.的董事会任职。Mead先生拥有拉法叶学院的学士学位和南加州大学的工商管理硕士学位。
Dana G. Mead, Jr.,served as the Chief Executive Officer, President and director of HeartFlow, Inc., a medical technology company. From November 2016 to May 2019, Mr. Mead served as President and Chief Executive Officer of Beaver-Visitec International, Inc., a surgical device developer and manufacturer. From June 2005 to November 2016, Mr. Mead served as a partner at Kleiner Perkins Caufield & Byers, a venture capital investment firm. In addition to serving on Pulmonx Corporation Board of Directors, Mr. Mead has served on the board of directors of Inari Medical, Inc. since October 2021 and the board of directors of Inspire Medical Systems since July 2008, where he serves on its audit committee. Mr. Mead also served on the board of directors of Inari Medical, Inc. from October 2021 until its sale to Stryker in February 2025 and Intersect ENT, Inc. from January 2006 until its sale to Medtronic, Inc. in May 2022. Mr. Mead holds a B.A. from Lafayette College and an M.B.A. from the University of Southern California. - Dana G. Mead, Jr.，自2008年7月起担任董事会成员。Mead先生于2019年5月至2021年2月担任HeartFlow，Inc.的首席执行官兼总裁，HeartFlow，Inc.是一家改变心脏病诊断和治疗方式的数字健康公司。2016年至2019年5月，Mead先生担任Beaver-Visitec International，Inc.的首席执行官兼总裁，Beaver-Visitec International，Inc.是一家外科手术设备开发商和制造商。从2005年到2016年，Mead先生在风险投资公司Kleiner Perkins Caufield & Byers担任合伙人。除了在董事会任职外，Mead先生自2015年6月起担任医疗技术公司Intersect ENT，Inc.的董事会成员，自2008年起担任Pulmonx Corporation的董事会成员。2011年5月至2016年12月，Mead先生在远程健康公司Teladoc, Inc.的董事会任职。Mead先生拥有拉法叶学院的学士学位和南加州大学的工商管理硕士学位。
- Dana G. Mead, Jr.,served as the Chief Executive Officer, President and director of HeartFlow, Inc., a medical technology company. From November 2016 to May 2019, Mr. Mead served as President and Chief Executive Officer of Beaver-Visitec International, Inc., a surgical device developer and manufacturer. From June 2005 to November 2016, Mr. Mead served as a partner at Kleiner Perkins Caufield & Byers, a venture capital investment firm. In addition to serving on Pulmonx Corporation Board of Directors, Mr. Mead has served on the board of directors of Inari Medical, Inc. since October 2021 and the board of directors of Inspire Medical Systems since July 2008, where he serves on its audit committee. Mr. Mead also served on the board of directors of Inari Medical, Inc. from October 2021 until its sale to Stryker in February 2025 and Intersect ENT, Inc. from January 2006 until its sale to Medtronic, Inc. in May 2022. Mr. Mead holds a B.A. from Lafayette College and an M.B.A. from the University of Southern California.
高管简历
中英对照 | 中文 | 英文- Chase Leavitt
Chase Leavitt自2026年2月起担任Mobia Medical，Inc.的总法律顾问和公司秘书。此前，Leavitt先生于2021年4月至2025年6月期间担任上市生物技术公司Oncternal Therapeutics, Inc.的总法律顾问和公司秘书。Leavitt先生还曾于2019年5月至2021年4月担任Lineage Cell Therapeutics, Inc.（NYSE：LCTX）的总法律顾问和公司秘书，该公司是一家上市的生物技术公司。Leavitt先生此前曾于2018年6月至2019年5月担任Tang Capital Management，LLC（一家专注于生命科学的投资公司）及其附属公司Odonate Therapeutics, Inc.（一家上市制药公司）的法律事务副总裁。Leavitt先生于2014年至2018年在科技公司Switch, Inc.担任的职务不断升级，最近通过该公司的首次公开发行担任副总法律顾问。Leavitt先生曾于2007年至2014年在Latham & Watkins LLP担任公司律师。Leavitt先生获得了南加州大学的工商管理学士学位和法学博士学位，并获准在加利福尼亚州、华盛顿州和德克萨斯州从事法律业务。
Chase Leavitt has served as Mobia Medical, Inc.'s General Counsel and Corporate Secretary since February 2026. Previously, Mr. Leavitt served as General Counsel and Corporate Secretary of Oncternal Therapeutics, Inc., a publicly traded biotechnology company, from April 2021 to June 2025. Mr. Leavitt also served as General Counsel and Corporate Secretary of Lineage Cell Therapeutics, Inc. (NYSE: LCTX), a publicly traded biotechnology company, from May 2019 to April 2021. Mr. Leavitt previously served as Vice President of Legal Affairs of Tang Capital Management, LLC, a life sciences focused investment company, and its affiliate Odonate Therapeutics, Inc., a publicly traded pharmaceutical company, from June 2018 to May 2019. Mr. Leavitt had escalating roles at Switch, Inc., a technology company, from 2014 to 2018, most recently as Deputy General Counsel through the company's initial public offering. Mr. Leavitt was a corporate attorney at Latham & Watkins LLP from 2007 to 2014. Mr. Leavitt received a B.S. in Business Administration and a J.D. from the University of Southern California and is admitted to practice law in the States of California, Washington, and Texas.- Chase Leavitt自2026年2月起担任Mobia Medical，Inc.的总法律顾问和公司秘书。此前，Leavitt先生于2021年4月至2025年6月期间担任上市生物技术公司Oncternal Therapeutics, Inc.的总法律顾问和公司秘书。Leavitt先生还曾于2019年5月至2021年4月担任Lineage Cell Therapeutics, Inc.（NYSE：LCTX）的总法律顾问和公司秘书，该公司是一家上市的生物技术公司。Leavitt先生此前曾于2018年6月至2019年5月担任Tang Capital Management，LLC（一家专注于生命科学的投资公司）及其附属公司Odonate Therapeutics, Inc.（一家上市制药公司）的法律事务副总裁。Leavitt先生于2014年至2018年在科技公司Switch, Inc.担任的职务不断升级，最近通过该公司的首次公开发行担任副总法律顾问。Leavitt先生曾于2007年至2014年在Latham & Watkins LLP担任公司律师。Leavitt先生获得了南加州大学的工商管理学士学位和法学博士学位，并获准在加利福尼亚州、华盛顿州和德克萨斯州从事法律业务。
- Chase Leavitt has served as Mobia Medical, Inc.'s General Counsel and Corporate Secretary since February 2026. Previously, Mr. Leavitt served as General Counsel and Corporate Secretary of Oncternal Therapeutics, Inc., a publicly traded biotechnology company, from April 2021 to June 2025. Mr. Leavitt also served as General Counsel and Corporate Secretary of Lineage Cell Therapeutics, Inc. (NYSE: LCTX), a publicly traded biotechnology company, from May 2019 to April 2021. Mr. Leavitt previously served as Vice President of Legal Affairs of Tang Capital Management, LLC, a life sciences focused investment company, and its affiliate Odonate Therapeutics, Inc., a publicly traded pharmaceutical company, from June 2018 to May 2019. Mr. Leavitt had escalating roles at Switch, Inc., a technology company, from 2014 to 2018, most recently as Deputy General Counsel through the company's initial public offering. Mr. Leavitt was a corporate attorney at Latham & Watkins LLP from 2007 to 2014. Mr. Leavitt received a B.S. in Business Administration and a J.D. from the University of Southern California and is admitted to practice law in the States of California, Washington, and Texas.
- Douglas Ellison
Douglas Ellison自2023年1月起担任Mobia Medical，Inc.首席商务官。在此之前，Ellison先生于2019年9月至2022年12月在医疗器械公司AtriCure，Inc.（纳斯达克：ATRC）担任混合疗法总监，监督其某些产品线的所有商业活动，并于2012年4月至2019年9月在SentreHEART，Inc.担任销售副总裁，建立其销售组织并发展其销售流程。埃里森先生获得了普渡大学的工程学学士学位。
Douglas Ellison has served as Mobia Medical, Inc.'s Chief Commercial Officer since January 2023. Previously, Mr. Ellison was Director of Hybrid Therapies at AtriCure, Inc. (Nasdaq: ATRC), a medical device company, from September 2019 to December 2022, overseeing all commercial activities for certain of its product line, and the Vice President of Sales at SentreHEART, Inc. from April 2012 to September 2019, building out its sales organization and developing its sales process. Mr. Ellison received a B.S. in Engineering from Purdue University.- Douglas Ellison自2023年1月起担任Mobia Medical，Inc.首席商务官。在此之前，Ellison先生于2019年9月至2022年12月在医疗器械公司AtriCure，Inc.（纳斯达克：ATRC）担任混合疗法总监，监督其某些产品线的所有商业活动，并于2012年4月至2019年9月在SentreHEART，Inc.担任销售副总裁，建立其销售组织并发展其销售流程。埃里森先生获得了普渡大学的工程学学士学位。
- Douglas Ellison has served as Mobia Medical, Inc.'s Chief Commercial Officer since January 2023. Previously, Mr. Ellison was Director of Hybrid Therapies at AtriCure, Inc. (Nasdaq: ATRC), a medical device company, from September 2019 to December 2022, overseeing all commercial activities for certain of its product line, and the Vice President of Sales at SentreHEART, Inc. from April 2012 to September 2019, building out its sales organization and developing its sales process. Mr. Ellison received a B.S. in Engineering from Purdue University.
- Nelson Bunker Curnes
Nelson Bunker Curnes自2009年起担任Mobia Medical，Inc.董事会成员，自2020年9月起担任Mobia Medical，Inc.的首席财务官。Curnes先生此前曾于2015年6月至2016年1月在TEGA技术有限责任公司担任首席运营官。Curnes先生在2010年8月至2015年3月期间还在波士顿咨询公司担任过不断升级的职务，包括负责人和项目负责人。Curnes先生获得了圣母大学机械工程学士学位和杜克大学Fuqua商学院工商管理硕士学位。
Nelson Bunker Curnes has served as a member of Mobia Medical, Inc.'s board of directors since 2009 and as Mobia Medical, Inc.'s Chief Financial Officer since September 2020. Mr. Curnes previously served as the Chief Operating Officer at TEGA Technologies, LLC from June 2015 to January 2016. Mr. Curnes also had escalating roles at The Boston Consulting Group including Principal and Project Leader from August 2010 to March 2015. Mr. Curnes received a B.S. in Mechanical Engineering from the University of Notre Dame and an M.B.A. from the Fuqua School of Business at Duke University.- Nelson Bunker Curnes自2009年起担任Mobia Medical，Inc.董事会成员，自2020年9月起担任Mobia Medical，Inc.的首席财务官。Curnes先生此前曾于2015年6月至2016年1月在TEGA技术有限责任公司担任首席运营官。Curnes先生在2010年8月至2015年3月期间还在波士顿咨询公司担任过不断升级的职务，包括负责人和项目负责人。Curnes先生获得了圣母大学机械工程学士学位和杜克大学Fuqua商学院工商管理硕士学位。
- Nelson Bunker Curnes has served as a member of Mobia Medical, Inc.'s board of directors since 2009 and as Mobia Medical, Inc.'s Chief Financial Officer since September 2020. Mr. Curnes previously served as the Chief Operating Officer at TEGA Technologies, LLC from June 2015 to January 2016. Mr. Curnes also had escalating roles at The Boston Consulting Group including Principal and Project Leader from August 2010 to March 2015. Mr. Curnes received a B.S. in Mechanical Engineering from the University of Notre Dame and an M.B.A. from the Fuqua School of Business at Duke University.
- Richard Foust
Richard Foust自2022年1月起担任Mobia Medical，Inc.董事会成员和Mobia Medical，Inc.首席执行官，并自2025年10月起担任Mobia Medical，Inc.总裁兼首席执行官。Mr. Foust co创立了3D Strategy Consulting，LLC，这是一家医疗保健咨询服务公司，自2015年2月起担任其首席执行官。Foust先生此前曾于2018年11月至2020年11月担任医疗设备公司Velano Vascular，Inc.的首席商务官，并于2015年5月至2018年2月担任数字健康公司Analyte Health，Inc.的首席商务官。Foust先生还在Abbott Vascular，Inc.担任过不断升级的职务，包括West Area Vascular销售高级总监和Vascular Global Marketing & BioResorbable Vascular Scaffold高级总监。Foust先生在埃默里大学获得应用物理学学士学位，在乔治亚理工学院获得生物工程专业的机械工程硕士学位。
Richard Foust has served as a member of Mobia Medical, Inc.'s board of directors and as Mobia Medical, Inc.'s Chief Executive Officer since January 2022 and has served as Mobia Medical, Inc.'s President and Chief Executive Officer since October 2025. Mr. Foust co founded 3D Strategy Consulting, LLC, a healthcare consulting services company, and has served as its Chief Executive Officer since February 2015. Mr. Foust previously served as the Chief Commercial Officer at Velano Vascular, Inc., a medical device company, from November 2018 to November 2020, and as the Chief Business Officer at Analyte Health, Inc., a digital health company, from May 2015 to February 2018. Mr. Foust also had escalating roles at Abbott Vascular, Inc., including Senior Director, West Area Endovascular Sales and Senior Director, Endovascular Global Marketing & Bioresorbable Vascular Scaffold. Mr. Foust received a B.S. in Applied Physics from Emory University and an M.S. in Mechanical Engineering with a major in Bioengineering from Georgia Institute of Technology.- Richard Foust自2022年1月起担任Mobia Medical，Inc.董事会成员和Mobia Medical，Inc.首席执行官，并自2025年10月起担任Mobia Medical，Inc.总裁兼首席执行官。Mr. Foust co创立了3D Strategy Consulting，LLC，这是一家医疗保健咨询服务公司，自2015年2月起担任其首席执行官。Foust先生此前曾于2018年11月至2020年11月担任医疗设备公司Velano Vascular，Inc.的首席商务官，并于2015年5月至2018年2月担任数字健康公司Analyte Health，Inc.的首席商务官。Foust先生还在Abbott Vascular，Inc.担任过不断升级的职务，包括West Area Vascular销售高级总监和Vascular Global Marketing & BioResorbable Vascular Scaffold高级总监。Foust先生在埃默里大学获得应用物理学学士学位，在乔治亚理工学院获得生物工程专业的机械工程硕士学位。
- Richard Foust has served as a member of Mobia Medical, Inc.'s board of directors and as Mobia Medical, Inc.'s Chief Executive Officer since January 2022 and has served as Mobia Medical, Inc.'s President and Chief Executive Officer since October 2025. Mr. Foust co founded 3D Strategy Consulting, LLC, a healthcare consulting services company, and has served as its Chief Executive Officer since February 2015. Mr. Foust previously served as the Chief Commercial Officer at Velano Vascular, Inc., a medical device company, from November 2018 to November 2020, and as the Chief Business Officer at Analyte Health, Inc., a digital health company, from May 2015 to February 2018. Mr. Foust also had escalating roles at Abbott Vascular, Inc., including Senior Director, West Area Endovascular Sales and Senior Director, Endovascular Global Marketing & Bioresorbable Vascular Scaffold. Mr. Foust received a B.S. in Applied Physics from Emory University and an M.S. in Mechanical Engineering with a major in Bioengineering from Georgia Institute of Technology.
- Prashant Rawat
Prashant Rawat自2022年6月起担任Mobia Medical，Inc.的首席运营官。此前，Rawat先生曾于2010年7月至2021年6月担任医疗器械公司Mainstay Medical International PLC的首席运营官。Rawat先生在巴罗达Maharaja Sayajirao大学获得电子学工程学士学位，在凯斯西储大学获得电气工程和应用物理硕士学位。
Prashant Rawat has served as Mobia Medical, Inc.'s Chief Operating Officer since June 2022. Previously, Mr. Rawat was the Chief Operating Officer at Mainstay Medical International plc, a medical device firm, from July 2010 to June 2021. Mr. Rawat received a Bachelor of Engineering in Electronics from the Maharaja Sayajirao University of Baroda and an M.S. in Electrical Engineering and Applied Physics at Case Western Reserve University.- Prashant Rawat自2022年6月起担任Mobia Medical，Inc.的首席运营官。此前，Rawat先生曾于2010年7月至2021年6月担任医疗器械公司Mainstay Medical International PLC的首席运营官。Rawat先生在巴罗达Maharaja Sayajirao大学获得电子学工程学士学位，在凯斯西储大学获得电气工程和应用物理硕士学位。
- Prashant Rawat has served as Mobia Medical, Inc.'s Chief Operating Officer since June 2022. Previously, Mr. Rawat was the Chief Operating Officer at Mainstay Medical International plc, a medical device firm, from July 2010 to June 2021. Mr. Rawat received a Bachelor of Engineering in Electronics from the Maharaja Sayajirao University of Baroda and an M.S. in Electrical Engineering and Applied Physics at Case Western Reserve University.